Comparative Study of Metaplastic Breast Carcinoma and Triple-Negative Breast Carcinoma Using Histologic and Immunohistochemical Analyses
2
조회
0
다운로드
1
인용
0
참고문헌
초록
Background : Metaplastic carcinoma of the breast is a rare subtype of breast cancer, which is characterized by estrogen receptor/progesterone receptor and HER2 negativity. Methods : Tissue specimens from 60 metaplastic breast cancer and 60 triple-negative breast cancer patients diagnosed at a single institution between 1995 and 2009 were analyzed. Immunohistochemistry for caveolin-1 (CAV-1), vascular endothelial growth factor (VEGF), epidermal growth factor receptor (EGFR), c-kit, p53, Ki-67, breast cancer type 1 susceptibility protein (BRCA1), cytokeratin (CK)14, and CK17 were performed on both retained tissue sets. Results : Of the 60 metaplastic carcinomas, 15 tumors (25%) exhibited spindle cell component, 27 (45%) exhibited chondroid differentiation, and 18 (30%) exhibited squamous areas. Compared to triple-negative carcinomas, metaplastic carcinomas significantly more frequently expressed CK14 (p < 0.0001), CK17 (p = 0.002), EGFR (p < 0.0001), CAV-1 (p < 0.0001), and VEGF (p = 0.029). However, expressions of BRCA1, p53, c-kit, and Ki-67 were not significantly different between both groups. Conclusions : The expression profile of metaplastic carcinoma of the breast is more homogeneous than that of other triple-negative tumors and frequently over-expresses basal markers, CAV-1, and VEGF. A typical “asal-like”phenotype and frequent expressions of CAV-1 and VEGF may justify specific therapeutic approaches.
Abstract
Background : Metaplastic carcinoma of the breast is a rare subtype of breast cancer, which is characterized by estrogen receptor/progesterone receptor and HER2 negativity. Methods : Tissue specimens from 60 metaplastic breast cancer and 60 triple-negative breast cancer patients diagnosed at a single institution between 1995 and 2009 were analyzed. Immunohistochemistry for caveolin-1 (CAV-1), vascular endothelial growth factor (VEGF), epidermal growth factor receptor (EGFR), c-kit, p53, Ki-67, breast cancer type 1 susceptibility protein (BRCA1), cytokeratin (CK)14, and CK17 were performed on both retained tissue sets. Results : Of the 60 metaplastic carcinomas, 15 tumors (25%) exhibited spindle cell component, 27 (45%) exhibited chondroid differentiation, and 18 (30%) exhibited squamous areas. Compared to triple-negative carcinomas, metaplastic carcinomas significantly more frequently expressed CK14 (p < 0.0001), CK17 (p = 0.002), EGFR (p < 0.0001), CAV-1 (p < 0.0001), and VEGF (p = 0.029). However, expressions of BRCA1, p53, c-kit, and Ki-67 were not significantly different between both groups. Conclusions : The expression profile of metaplastic carcinoma of the breast is more homogeneous than that of other triple-negative tumors and frequently over-expresses basal markers, CAV-1, and VEGF. A typical “asal-like”phenotype and frequent expressions of CAV-1 and VEGF may justify specific therapeutic approaches.
참고문헌 (30)
- McKeage K, "Trastuzumab:a review of its use in the treatment of metastatic breast cancer overexpressing HER2", Drugs, 62, pp.209~243 (2002)
- Slamon DJ, "Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2", N Engl J Med, 344, pp.783~792 (2001)
- Rosen PP, "Rosen’s breast pathology", pp.470~505 (2009), Lippincott Williams & Wilkins, a Wolters Kluwer business
- Jung SY, "Worse prognosis of metaplastic breast cancer patients than other patients with triple-negative breast cancer", Breast Cancer Res Treat, 120, pp.627~637 (2010)
- Pezzi CM, "Characteristics and treatment of metaplastic breast cancer:analysis of 892 cases from the National Cancer Data Base", Ann Surg Oncol, 14, pp.166~173 (2007)
- Allred DC, "Prognostic and predictive factors in breast cancer by immunohistochemical analysis", Mod Pathol, 11, pp.155~168 (1998)
- Wargotz ES, "Metaplastic carcinomas of the breast:I.matrixproducing carcinoma", Hum Pathol, 20, pp.628~635 (1989)
- Wargotz ES, "Metaplastic carcinomas of the breast:II.spindle cell carcinoma", Hum Pathol, 20, pp.732~740 (1989)
- Wargotz ES, "Metaplastic carcinomas of the breast:III.carcinosarcoma", Cancer, 64, pp.1490~1499 (1989)
- Wargotz ES, "Metaplastic carcinomas of the breast:IV.squamous cell carcinoma of ductal origin", Cancer, 65, pp.272~276 (1990)
- Wargotz ES, "Metaplastic carcinomas of the breast:V.metaplastic carcinoma with osteoclastic giant cells", Hum Pathol, 21, pp.1142~1150 (1990)
- Osako T, "Histogenesis of metaplastic breast carcinoma and axillary nodal metastases", Pathol Int, 59, pp.116~120 (2009)
- Oberman HA, "Metaplastic carcinoma of the breast:a clinicopathologic study of 29 patients", Am J Surg Pathol, 11, pp.918~929 (1987)
- Yamaguchi R, "Clinicopathologic study of 53 metaplastic breast carcinomas:their elements and prognostic implications", Hum Pathol, 41, pp.679~685 (2010)
- Downs-Kelly E, "Matrix-producing carcinoma of the breast:an aggressive subtype of metaplastic carcinoma", Am J Surg Pathol, 33, pp.534~541 (2009)
- Weigelt B, "Refinement of breast cancer classification by molecular characterization of histological special types", J Pathol, 216, pp.141~150 (2008)
- SOrlie T, "Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications", Proc Natl Acad Sci U S A, 98, pp.10869~10874 (2001)
- Sorlie T, "Repeated observation of breast tumor subtypes in independent gene expression data sets", Proc Natl Acad Sci U S A, 100, pp.8418~8423 (2003)
- Sotiriou C, "Breast cancer classification and prognosis based on gene expression profiles from a population-based study", Proc Natl Acad Sci U S A, 100, pp.10393~10398 (2003)
- Rakha EA, "Triple-negative", basal-like breast cancer:review, 2009, pp.41, 40~47
- Reis-Filho JS, "Metaplastic breast carcinomas are basal-like tumours", Histopathology, 49, pp.10~21 (2006)
- Weigelt B, "Metaplastic breast carcinomas are basal-like breast cancers:a genomic profiling analysis", Breast Cancer Res Treat, 117, pp.273~280 (2009)
- Leibl S, "Metaplastic breast carcinomas are negative for Her-2 but frequently express EGFR (Her-1): potential relevance to adjuvant treatment with EGFR tyrosine kinase inhibitors?", J Clin Pathol, 58, pp.700~704 (2005)
- Savage K, "Caveolin 1 is overexpressed and amplified in a subset of basal-like and metaplastic breast carcinomas:a morphologic,ultrastructural,immunohistochemical,and in situ hybridization analysis", Clin Cancer Res, 13, pp.90~101 (2007)
- Baselga J, "Critical update and emerging trends in epidermal growth factor receptor targeting in cancer", J Clin Oncol, 23, pp.2445~2459 (2005)
- Ferrara N, "Bevacizumab(Avastin),a humanized anti-VEGF monoclonal antibody for cancer therapy", Biochem Biophys Res Commun, 333, pp.328~335 (2005)
- Petrelli F, "Current data of targeted therapies for the treatment of triple-negative advanced breast cancer:empiricism or evidence-based?", Barni S, 18, pp.1467~1477 (2009)
- Lisanti MP, "Caveolae,caveolin and caveolin-rich membrane domains:a signalling hypothesis", Trends Cell Biol, 4, pp.231~235 (1994)
- Pramudji C, "In situ prostate cancer gene therapy using a novel adenoviral vector regulated by the caveolin-1 promoter", Clin Cancer Res, 7, pp.4272~4279 (2001)
- Boccadoro M, "Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy", Cancer Cell Int, 5, pp.18~ (2005)